What is the appropriate treatment approach for a benign meningioma?

Treatment of Benign Meningioma

For benign (WHO grade 1) meningiomas, gross total resection remains the preferred treatment when achievable with minimal morbidity, but stereotactic radiosurgery (SRS) is now an evidence-based primary treatment option (not just adjuvant therapy) with 10-year local control rates of 71-100% and should be strongly considered for skull base tumors, surgically inaccessible lesions, or when surgery carries significant risk. 1

Treatment Algorithm

Step 1: Determine if Active Treatment is Needed

• Elderly or asymptomatic patients with small tumors: Observation with serial MRI is often the best option 2, 3
• Symptomatic patients or those with significant mass effect: Proceed to active treatment

Step 2: Select Primary Treatment Modality

The choice depends on tumor characteristics and surgical accessibility:

Surgical Resection (First-Line for Accessible Tumors)

• Goal: Gross total resection (GTR) including involved dura 2

• Best candidates:

  • Parasagittal, lateral sphenoid wing, olfactory groove meningiomas 4
  • Tumors causing acute symptoms requiring decompression 5
  • Younger patients with resectable tumors and minimal surgical morbidity risk 2

• Consider subtotal resection with nerve preservation for:

  • Petroclival, parasellar, posterior fossa locations 4
  • Cavernous sinus involvement 4
  • Tumors where GTR would sacrifice cranial nerves 3

• Preoperative embolization may reduce bleeding and complications 4

Stereotactic Radiosurgery (Primary or Adjuvant)

• Prescription dose: 12-15 Gy in single fraction 1

• Outcomes:

  • 5-year progression-free survival: 85-100% (median 89%)
  • 10-year progression-free survival: 53-100% (median 85%)
  • Low toxicity rates 1

• Primary SRS is preferred for:

  • Small tumors (typically <3-3.5 cm) 6
  • Skull base locations where surgery is difficult 6
  • Patients who are poor surgical candidates 1
  • Tumors without tissue diagnosis when imaging is characteristic 1

• Adjuvant SRS after subtotal resection provides tumor control comparable to other approaches 5, though previous surgery may adversely affect outcomes 1

Fractionated Stereotactic Radiotherapy (SRT/HSRT)

• Standard fractionation: 1.8-3.0 Gy per fraction over 5-6 weeks 1

• Hypofractionated: Most common is 25 Gy in 5 fractions 1

• Indications:

  • Larger tumors (>3-3.5 cm) 6
  • Tumors closely approximating optic chiasm or brainstem 6
  • Optic nerve sheath meningiomas (preferred primary treatment) 5
  • Previously treated tumors 2

• Outcomes: >90% 5-year tumor control, toxicity equivalent to SRS despite treating larger/more complex volumes 6

Step 3: Postoperative Surveillance

The 2025 evidence-based framework provides specific guidance 7:

Immediate Post-Treatment

• MRI at 48 hours to determine extent of resection 7
• MRI at 4 months to detect rapid regrowth 7

Long-Term Surveillance for Completely Resected Grade 1 Meningiomas

• Annual MRI for 11 years, then discontinue if no recurrence 7
• Rationale: 5-year recurrence rate 10%, 10-year rate 20%, no recurrences beyond 11 years 7

Incompletely Resected Meningiomas (Any Grade)

• Indefinite surveillance as recurrences occur throughout observation period 7

Imaging Modality

• MRI without and with IV contrast is the standard 8
• DOTATATE PET/CT may provide more accurate delineation of resection extent, particularly for WHO grade 2/3 tumors, but should be reserved for new findings on surveillance MRI 8

Critical Pitfalls to Avoid

1. Don't assume surgery is always superior: The evidence now supports SRS as a primary treatment option with excellent long-term control, not just salvage therapy 1

2. Don't pursue aggressive GTR at all costs: For skull base locations, subtotal resection with nerve preservation followed by radiation provides better functional outcomes than aggressive resection with cranial nerve sacrifice 3

3. Don't stop surveillance too early for completely resected Grade 1 tumors: Elevated recurrence rates persist beyond 5 years, requiring 11 years of follow-up 7

4. Don't use the same surveillance schedule for all grades: Completely resected Grade 1 meningiomas can stop surveillance at 11 years, but incompletely resected tumors require indefinite follow-up 7

Evidence Quality Considerations

The 2020 International Stereotactic Radiosurgery Society guideline acknowledges that SRS literature lacks level I and II evidence, but the large body of level III studies (27 studies, 2844 reviewed) provides sufficient consensus to recommend SRS as an effective evidence-based treatment option (recommendation level II) 1. The consistency of outcomes across multiple retrospective series (10-year local control 71-100%) provides robust support for this approach despite the absence of randomized trials.